ACC: Ionis’ rare metabolic disorder drug slides from 100% efficacy, but FDA ambitions unchanged
ACC: Ionis’ rare metabolic disorder drug slides from 100% efficacy, but FDA ambitions unchanged gmasson Fri, 04/05/2024 - 16:39
ACC: Ionis’ rare metabolic disorder drug slides from 100% efficacy, but FDA ambitions unchanged gmasson Fri, 04/05/2024 - 16:39
Deep dive: Biopharma layoffs in Q1 aellison Fri, 04/05/2024 - 16:18
BMS' newly acquired schizophrenia drug showed continued symptom improvement in open-label studies mbayer Fri, 04/05/2024 - 15:20
Gene suppression prevents some types of brain damage in mice and human organoids hfloersh Fri, 04/05/2024 - 14:26
AACR: Mural debuts preclinical data for potential cytokine therapy pipeline additions hfloersh Fri, 04/05/2024 - 12:03
Contineum lowers expectations for $110M IPO as J&J-allied biotech goes public jwaldron Fri, 04/05/2024 - 06:40
Sanofi begins 'full pipeline reprioritization' with layoffs in tow, R&D chief tells staff mbayer Fri, 04/05/2024 - 00:26
AACR: Regeneron’s multiple myeloma drug shows staying power, just after FDA accepts it for quick review aarmstrong Thu, 04/04/2024 - 20:05